Autoimmune Diseases  >>  Lemtrada (alemtuzumab)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lemtrada (alemtuzumab) / Sanofi
NCT01395316: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

Completed
4
8
NA
Alemtuzumab, CamPath, MabPath
University of Chicago, Genzyme, a Sanofi Company
Multiple Sclerosis
10/15
07/17
EMERALD, NCT02205489 / 2014-000092-62: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Checkmark ECTRIMS 2015: Multiple sclerosis (EMERALD)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (EMERALD)
Completed
4
58
Europe
Alemtuzumab GZ402673, Lemtrada, cetirizine, ranitidine, methylprednisolone, aciclovir, esomeprazole, ibuprofen, paracetamol
Genzyme, a Sanofi Company
Relapsing-remitting Multiple Sclerosis
04/16
04/16

Download Options